Evidence map›Paper›PMID 36831046›Full record

ArticleBiomedicines2023

Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study.

Francesca La Gualana, Francesca Maiorca, Ramona Marrapodi, Francesca Villani, Marzia Miglionico, Stefano Angelo Santini, Fabio Pulcinelli, Laura Gragnani, Silvia Piconese, Massimo Fiorilli and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Francesca La GualanaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Francesca MaiorcaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Ramona MarrapodiDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Francesca VillaniDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Marzia MiglionicoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Stefano Angelo SantiniDepartment of Basic, Clinical, Intensive and Perioperative Biotechnological Sciences, Catholic University, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Fabio PulcinelliDepartment of Experimental Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Laura GragnaniMASVE Interdepartmental Center, Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.ORCID 0000-0001-6800-9149
Silvia PiconeseDepartment of Internal Clinical Sciences, Anaesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.ORCID 0000-0002-9685-5227
Massimo FiorilliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Stefania BasiliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.ORCID 0000-0002-6987-1926
Milvia CasatoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Lucia StefaniniDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.ORCID 0000-0001-7420-301X
Marcella VisentiniDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, Italy.
Sapienza University of Rome · ITAgostino Gemelli University Polyclinic · ITUniversity of Florence · IT

Funding

Sapienza University of Rome RM11916B7567F9E4Sapienza University of Rome RM120172B8BE02DA
6 · The paper itself

Abstract

New-generation mRNA and adenovirus vectored vaccines against SARS-CoV-2 spike protein are endowed with immunogenic, inflammatory and immunomodulatory properties. Recently, BioNTech developed a noninflammatory tolerogenic mRNA vaccine (MOGm1Ψ) that induces in mice robust expansion of antigen-specific regulatory T (Treg) cells. The Pfizer/BioNTech BNT162b2 mRNA vaccine against SARS-CoV-2 is identical to MOGm1Ψ except for the lipid carrier, which differs for containing lipid nanoparticles rather than lipoplex. Here we report that vaccination with BNT162b2 led to an increase in the frequency and absolute count of CD4

Indexed as

immunogenicityregulatory T-cellsSARS-CoV-2toleranceTregvaccines

Identifiers

PMID36831046
PMCPMC9953737
OpenAlexW4319964327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.